Acumen Pharmaceuticals, Inc. exercised its option under a collaboration agreement with JCR Pharmaceuticals Co. Ltd. to license and develop two enhanced brain delivery (EBD) candidates for Alzheimer’s disease treatment. The selected candidates include a bispecific antibody derived from sabirnetug and a next-generation amyloid-beta oligomer-selective antibody, ACU234. Preclinical studies in murine and non-human primate models showed antibody levels 14-40x higher in non-human primates than native antibodies at 24 hours, with favorable stability and low anemia risk. Acumen Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases.